Sadie Whittaker
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
 | This article is a stub. |
Dr. Sadie Whittaker, is the Chief Scientific Officer of Solve ME/CFS Initiative (SMCI). She received her PhD in molecular biology at University of Birmingham, UK, and her BSc in Biochemistry from University of Leeds, UK. She worked first as a medical writer for Amgen before rising to the Director of Clinical Development and finally to US Medical Lead for Biosimilars there. Thereafter, she founded ScienceOne, where she served as CEO.
Dr. Whittaker joined Solve ME/CFS Initiative (SMCI) in May 2018, where she manages the Ramsay grants and serves as SMCI’s liaison with the National Institutes of Health (NIH) Collaborative Research Centers (CRCs) and Data Management Coordination Center (DMCC).
Notable studies[edit | edit source]
Advocacy[edit | edit source]
Open letter to The Lancet[edit | edit source]
- 19 June 2018, Sadie Whittaker signed an open letter to the editor of The Lancet urging the editor to commission a fully independent review of the PACE trial, which the journal published in 2011.[1]
Talks and interviews[edit | edit source]
- Nov 1, 2019 Thinking Bigger and Bigger: Solve ME's Research Director Sadie Whittaker Talks On Moving Forward on ME/CFS on Health Rising
- May 3, 2019 - Q&A with Dr Sadie Whittaker from Solve ME/CFS Initiative, May 2019, with Science for ME
- Apr 12, 2019 - Episode 106, Interview with Sadie Whittaker, Chief Scientific Officer, Solve ME/CFS Initiative on MECFS Alert
Online presence[edit | edit source]
Learn more[edit | edit source]
See also[edit | edit source]
References[edit | edit source]
- ↑ Tuller, David (June 19, 2018). "Trial By Error: An Open Letter to The Lancet, Two Years On".
